Express Pharma

Zydus gains final USFDA approval for Valbenazine Capsules

Valbenazine Capsules had annual sales of $ 1,993.6 million in the United States (IQVIA MAT June 2024)

0 129

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Valbenazine Capsules, 40 mg, 60 mg, and 80 mg (USRLD: Ingrezza Capsules). Valbenazine Capsules are indicated for the treatment of adults with tardive dyskinesia (uncontrollable movement of the face, tongue, or other body parts). 

Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Valbenazine Capsules, 40 mg, and 80 mg, and was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Valbenazine Capsules, 60 mg. With this approval, Zydus is eligible for 180 days of shared generic drug exclusivity for Valbenazine Capsules, 40 mg, and 80 mg, and is eligible for 180 days of sole generic drug exclusivity for Valbenazine Capsules, 60 mg. 

Valbenazine Capsules had annual sales of $ 1,993.6 million in the United States (IQVIA MAT June 2024). The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ – II, India.

- Advertisement -